focus -WSS

focus

author：comprehensive 2025-10-02 13:13:51 - browse：699

Business standing in the middle of a maze near a bag with a dollar sign on it. -- biotech coverage from STAT — Adobe

Over the last year or two, something curious has started occurring in the conference rooms and private Zoom meetings of biotech venture capitalists.

Representatives from pension funds, college endowments, family offices, and other organizations with money to invest have become bolder in their requests, according to interviews with a host of VCs. They’re pushing not only for advantageous terms in a VC firm’s latest fund, but in some cases, have angled for equity in the firm itself. These types of conditions aren’t unheard of, but have become more frequent as venture capitalists have a harder time raising funds, and as outside investors feel empowered to ask for more bang for their buck.

“A lot is changing in venture fundraising right now,” said Nan Li, co-founder and managing partner of Dimension, which launched last January. Outside investors tried to ask for a piece of Dimension, but the new firm had more than enough interest in its first fund and was able to turn down those proposals. Two other young VC firms told STAT they’ve fielded similar requests, and one investment group reported that it had managed to negotiate an equity stake in a VC firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： U.S. death rates show how politics are affecting public health

entertainment

WSS

Why some fertility treatments produce more boy babies

U.S. death rates show how politics are affecting public health

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

The Bio Revolution is changing business and society

UCLA team creates talking throat patch for voice disorders

RaDonda Vaught links Vanderbilt hospital issues to patient death

focus

focus

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Sports medicine is finally prioritizing gender equality

John Green on his newest strategy for fighting tuberculosis

23andMe had bad news about my health. I wish a person had delivered it

Pushing for an NIH office for post

The cancer drug shortage isn’t new — and neither are the solutions

How to save health care price transparency rules

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

U.S. death rates show how politics are affecting public health

hotspot

As AI in medicine takes off, can 'human in the loop' prevent harm?

Stroke rates rising, especially in working

As AI in medicine takes off, can 'human in the loop' prevent harm?

Ebola: Gilead Sciences antiviral shows promise as new treatment

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

First U.S. drug developed to treat liver disease MASH is approved

entertainment

knowledge

hotspot

explore